Radiopharm Theranostics (NASDAQ:RADX) Now Covered by Analysts at Brookline Capital Management

Brookline Capital Management initiated coverage on shares of Radiopharm Theranostics (NASDAQ:RADX) in a research note issued to investors on Monday,Benzinga reports. The firm issued a buy rating and a $18.00 price objective on the stock.

Several other research firms have also issued reports on RADX. Maxim Group assumed coverage on Radiopharm Theranostics in a research report on Thursday, May 1st. They issued a “buy” rating and a $12.00 price target on the stock. ThinkEquity upgraded shares of Radiopharm Theranostics to a “strong-buy” rating in a report on Monday, May 12th.

Radiopharm Theranostics Trading Down 2.7%

Shares of Radiopharm Theranostics stock opened at $4.31 on Monday. The stock’s 50 day moving average is $4.55. Radiopharm Theranostics has a one year low of $3.50 and a one year high of $50.82.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.